%0 Journal Article
%T Predictors of switching from beta-blockers to other anti-hypertensive drugs: a review of records of 19,177 Chinese patients seen in public primary care clinics in the New Territory East, Hong Kong
%A Martin CS Wong
%A Harry HX Wang
%A Johnny Y Jiang
%A Stephen Leeder
%A Sian M Griffiths
%J Asia Pacific Family Medicine
%D 2011
%I BioMed Central
%R 10.1186/1447-056x-10-10
%X We used a validated database which consisted of the demographic and clinical information of all Chinese patients prescribed a beta-blocker from any public, family practice clinics between 01 Jan 2004 to 30 June 2007 in one large Territory of Hong Kong. The proportion of patients switched from beta-blockers to another antihypertensive agent 180 days within their first prescription was studied, and the factors associated with medication switching were evaluated by using multivariate regression analyses.From 19,177 eligible subjects with a mean age of 59.1 years, 763 (4.0%) were switched from their beta-blockers within 180 days of commencing therapy. A binary logistic regression model used medication switching as the outcome variable and controlled for age, gender, socioeconomic status, clinic setting (general out-patient clinics, family medicine specialist clinic or staff clinics), district of residence, visit type (new vs. follow-up attendance), the number of concomitant co-morbidities, and the calendar year of prescription. It was found that older patients (age 50-59 years: adjusted odds ratio [AOR] 1.38, 95% C.I. 1.12-1.70; p = 0.002; age 60-69 years: AOR 1.63 95% C.I. 1.30-2.04, p < 0.001; age ¡Ý 70 years: AOR 1.82, 95% C.I. 1.46-2.26, p < 0.001; referent age < 50 years) and new visitors (AOR 0.57, 95% C.I. 0.48-0.68, p < 0.001) were more likely to have their medication switched.Closer monitoring of the medication taking behavior among the older patients and the new clinic visitors prescribed a beta-blocker is warranted. Future studies should evaluate the reasons of drug switching.Hypertension is a global health problem and represents one of the most important, modifiable risk factors for renal and cardiovascular diseases [1] It affects more than 30% of the general US population [2], and estimates of the cost of the disorder are around $66.4 billion worldwide in 2007 [3]. Its prevalence is high over the globe, including Asia Pacific countries [4]. Despite the effec
%K beta-blocker
%K switching
%K pharmacoepidemiology
%K family practice
%U http://www.apfmj.com/content/10/1/10